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The presence of donor human leukocyte antigen (HLA)-speciﬁc antibodies (DSA) increases engraftment failure
risk in partially HLA-mismatched, or HLA-haploidentical, allogeneic marrow (alloBMT) transplantation. As pre-
existing sensitization to HLA antigens is not well characterized among candidates for HLA-haploidentical
alloBMT, we retrospectively evaluated both the incidence and relative strength of DSA in this patient pop-
ulation. Based on correlations of solid-phase antibody assays on the Luminex (Luminex, Austin, TX) platform
with actual crossmatch tests, DSA were characterized as weak for results that were consistent with negative
ﬂow cytometric crossmatch results or as moderate-to-strong for results consistent with positive ﬂow cyto-
metric or cytotoxicity crossmatches. We evaluated 296 alloBMT candidates; 111 (37.5%) were female. DSAwere
detected in 43 (14.5%) candidates, mostly among female candidates (42.9% female versus 12.5% male).
Moderate-to-strong DSA strength was more frequently encountered when directed against haploidentical
donors as comparedwithmismatched unrelated donors. DSAweremost commonly detected in female patients
directed against their children. Because the presence of DSA has been considered prohibitive for HLA-
mismatched alloBMT, we additionally report a desensitization methodology used to reduce DSA to negative
or weak levels, ie, levels well below those detectable in a ﬂow cytometric crossmatch. Nine patients without
other available donors underwent desensitization. Eight who reduced their DSA to negative or weak levels
proceeded to alloBMT and achieved full donor engraftment. These data support routine DSA evaluation in all
patients considered for mismatched alloBMT; however, for patients with no other viable options, desensiti-
zation to weak or negative DSA levels may afford the opportunity for successful transplantation.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION haploidentical related donor bone marrow transplantation
Allogeneic blood or marrow transplantation (alloBMT) is
a potentially curative treatment for many hematologic
malignances [1]. Historically, graft-versus-host disease
(GVHD) has constrained the applicability and availability of
alloBMT. Despite large international unrelated donor regis-
tries, nearly half of searches fail to identify a suitable
matched donor [2] and only a minority of registry donor
searches are successful for some ethnic groups, such as
African-Americans [3]. Evenwhen a match is found, National
Marrow Donor Program data indicate a median of 4 months
is required to complete searches; thus, patients can succumb
to disease during the process [2]. These limitations gave
impetus for the identiﬁcation of alternative allograft sources.
Translational studies show high-dose cyclophosphamide
early after alloBMT effectively modulates alloreactivity, even
in partially human leukocyte antigen (HLA)-mismatched
donor-recipient pairs [4-6]. By utilizing high-dose post-
transplantation cyclophosphamide, the normally prohibitive
complication of severe GVHD associated with partially HLA-
mismatched alloBMT is reduced to rates observed in fully
HLA-matched transplants [5]; in fact, increasing HLA
mismatch does not appear to be associated with increased
GVHD [6]. Importantly, the safety and efﬁcacy ofdgments on page 652.
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13.01.016(BMT) utilizing high-dose post-BMT cyclophosphamide was
conﬁrmed by the BMT Clinical Trials Network and other
studies [7].
Over 95% of patients, regardless of ethnicity, have readily
available, potential related haploidentical donors among
their parents, children, and siblings. In 2009, mismatched
alloBMT represented 5% of the alloBMT procedures per-
formed in the United States for acute myeloid leukemia [8],
but represented 65% of all the alloBMT performed at the
Sidney Kimmel Comprehensive Cancer Center (SKCCC) at
Johns Hopkins. In 2011, that percentage increased to 76%.
However, the use of partially HLA-mismatched donors
for alloBMT raises a barrier previously limited to solid organ
transplantation recipientsdantibody-meditated (graft) re-
jection. Patients sensitized through transfusion, pregnancy, or
previous transplantations to the mismatched HLA antigens
can produce donor HLA-speciﬁc antibodies (DSA). In solid
organ transplantation, DSA are associated with increased
ratesof antibody-mediated rejectionandareoften considered
a contraindication to transplantation [9]. Similarly, the pres-
ence of DSA before alloBMT, as detected by a positive cross-
match test (serum complement-ﬁxing antidonor antibodies),
increases the rate of engraftment failure, presumably due to
antibody-mediated rejection [10,11]. Recent studies employ-
ing highly sensitive solid-phase immunoassays utilizing
solubilized HLA antigens as targetsda more sensitive DSA
assay than the crossmatch testdreveal a greater than 10-fold
increased risk of engraftment failure in allogeneic BMT with
DSA [12-16].Transplantation.
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in patients considered for haploidentical alloBMT at the
SKCCC at Johns Hopkins and describe an effective method of
reducing DSA in patients being considered for alloBMT.
METHODS
Cohort Selection
After IRB approval, we retrospectively reviewed HLA antibody results for
individuals who were screened for haploidentical alloBMT at the SKCCC
between January 2006 and March 2011. For the ﬁrst 214 consecutive hap-
loidentical alloBMT candidates screened, eligibility required the absence of
readily available HLA-matched related or unrelated donor. Subsequently,
a potential matched unrelated donor was not a contraindication to related
haploidentical transplantation screening. Thereafter, our institutional
standard for alloBMT donor screening changed to evaluate 5 donors at initial
screening. If fewer than 5 siblings were evaluable, partially HLA-matched
related donors (parents, children were or half-siblings) were also evalu-
ated. Thus, the subsequent 82 alloBMT candidates had simultaneous sibling,
unrelated, and haploidentical donor searches. The presence of DSA was
considered as an exclusion criterion for potential donors, except for 9
patients with no other donor options who underwent desensitization.
HLA Typing
Patients and donors were HLA typed at the HLA-A, B, C, DRB1, DRB3-5,
DQB1, and DPB1 loci. Typing was performed using a combination of
reverse sequence speciﬁc oligonucleotide probe hybridization assays (One
Lambda, Inc., Canoga Park, CA) on the Luminex 100 instrument (Luminex,
Austin, TX) and high resolution using Sanger Sequencing BigDye V1.1
Terminator reagents (Applied Biosystems, Foster City, CA) with local and
commercial (Abbott Molecular, Abbott Park, IL) assays on the 3500 Genetic
Analyzer (Applied Biosystems, Foster City, CA).
Crossmatch Tests
Patient sera were crossmatched against lymphocytes from potential
donors at the time of their initial evaluation and within 1 week before
alloBMT. The crossmatch techniques used were standard complement
dependent cytotoxicity assays and/or ﬂow cytometric crossmatch tests. The
cytotoxicity assays were an antiglobulin enhanced test against donor T
lymphocytes and a 1-wash, basic crossmatch against donor B cells. The ﬂow
cytometric crossmatch, which is substantially more sensitive than a cyto-
toxicity test, was used to detect reactivity in patients with lower antibody
levels. Theﬂowcytometric assaywas performedby3-colorﬂuorescence after
gating on the lymphocyte population. Details of the crossmatch tests have
beenpreviously reported [17]. Interpretation of crossmatch resultswasmade
in conjunction with analysis of the presence of any donor HLA-speciﬁc anti-
bodies measured with solid-phase immunoassays, described below.
Analysis of HLA-Speciﬁc Antibodies
HLA-speciﬁc antibodies were assessed by solid-phase immunoassays on
the Luminex platform. The target antigens included pooled HLA antigens,
single HLA class I or class II phenotypes, and single HLA antigens (GenProbe
Lifecodes, Inc., San Diego, CA; One Lambda, Inc., Canoga Park, CA). To reduce
interference in the HLA single-antigen assays, euglobulins were depleted
from test sera by hypotonic dialysis before testing [18].
Estimates of relative antibody strength measured by degrees of reac-
tivity in solid-phase immunoassays were based on prior correlations with
crossmatch test results [17,19]. For the retrospective analysis of antibody
frequencies, reactions with test beads yielding mean ﬂuorescent intensities
(MFI) of 1000 were considered positive. Although the sensitivity of
detection varies for different HLA antibodies, in general, positive ﬂow
cytometric crossmatch tests correlated with the following MFI values from
the solid-phase immunoassays: 5000 on phenotype panels, and 10,000
to 15,000 on single-antigen panels. Positive complement-dependent cyto-
toxicity crossmatch (CDC) results were associated with 10,000 MFI on
phenotype panels. For comparisons of DSA, results from assays on pheno-
type panels were used as the primary criterion, as these assays have been
shown to give better correlations with crossmatch tests than do results from
the single-antigen panels [17]. Antibodies that would likely yield negative
ﬂowcytometric crossmatch testswere categorized asweakwhenMFI values
were from 1000 to 3000 on HLA phenotype panels. Antibodies were
considered moderate-to-strong when MFI values were >3000 on HLA
phenotype panels, as these values were predicatively consistent with posi-
tive crossmatch results. Because the immunoassays have been enhanced for
detection of antibodies to HLA-C, -DQ, and-DP antigens, higher cutoff values
for these antibody speciﬁcities were used [17]. Antibodies to HLA-DP anti-
gens were assessed on single-antigen panels, as these antigens are not
included on the phenotype panel assays.In addition to antibody strength, the breadth of HLA sensitization or the
number of antibodies to different HLA antigenswas assessed to determine the
extent to which HLA antibodies might limit a candidate’s HLA-mismatched
donor options. The breadth of sensitization was measured by a calculated
panel reactive antibody (CPRA), which was developed as a measure of
sensitization among solid organ transplant candidates and is derived from the
frequencies of HLA antigens among potential donors that correspond to the
HLA speciﬁc antibodies identiﬁed for each candidate [20]. In this analysis,
CPRA values were based only on antibodies sufﬁcient in strength to be
crossmatch positive. Statistical evaluation of differences in the incidence of
HLA antibodies among different patient subgroups was by chi-square tests.
Desensitization Methodology
For sensitized patients with moderate-to-strong DSA levels, and for
whom no other donors were identiﬁable, desensitization was initiated. The
desensitization treatment was based on the protocol developed for renal
transplant candidates at the Johns Hopkins Comprehensive Transplant Center
[21-23] and included alternate-day, single-volume plasmapheresis (PP) with
anti-CMV hyper-intravenous immune immunoglobulin (IVIg) (100 mg/kg),
tacrolimus (1 mg, IV per day) and mycophenolate mofetil (1 g, twice daily)
starting 1 to 2 weeks before the beginning of BMT conditioning, depending
upon each patient’s starting DSA levels. The number of PP/IVIg treatments
planned for each patient was based on experience with desensitization of
renal transplant candidates with modiﬁcations to accommodate the BMT
conditioning [22]. The number of PP/IVIg treatments was estimated based on
the starting donor speciﬁc antibody levels correlated with ﬂow cytometric or
CDC crossmatch tests. As PP could not be given during the pretransplantation
conditioning, nor with the post-transplantation cyclophosphamide on
daysþ3 andþ4, treatments were given before conditioningwith 1 additional
treatment on the day before infusion. A total of 4 or 5 treatments were
planned for patients with antibodies at ﬂow cytometric crossmatch positive
levels: 3 or 4 treatments performed before conditioning with an additional
treatment on day 1. A total of 7 treatments were planned for 1 patient who
had a CDC-crossmatch positive titer of 8. The number of treatments was
increased for 1 patient because of a delay in the availability of an unrelated
donor. Additional risk factors, such as child-to-mother transplantations or
repeat mismatches, were also considered in planning the number of treat-
ments. For patients exhibiting a rebound of their DSA on day 1, 1 or 2
additional PP/IVIG treatments were performed on days þ1 and þ2. Thera-
peutic plasma exchange was performed using the COBE Spectra (TerumoBCT,
Lakewood, CO), exchanging 1 plasma volume and replacing at 100% volume
with 5% albumin. The tacrolimus and mycophenolate mofetil were dis-
continued on the day before transplantation (day 1). Patient 4 additionally
received 4 infusions of bortezomib 151/2 weeks before initiation of
desensitization.
Conditioning and Primary GVHD Prophylaxis Regimen
Nonmyeloablative conditioning consisted of cyclophosphamide (14.5
mg/kg/day) on days 6 and 5, ﬂudarabine (30 mg/m/day) on days 5
through 2, total body irradiation (200 cGy) on day 1, infusion of an
unmanipulated bone marrow graft (target 4.0 x 108 nucleated cells/kg
recipient ideal body weight) on day 0, cyclophosphamide (50 mg/kg) on
days þ3 and þ4, mycophenolate mofetil on days þ5 through þ35, tacroli-
mus on daysþ5 through dayþ180, and ﬁlgrastim (5 mcg/kg/day) on dayþ5
through neutrophil recovery (>1000/mL) [5,7].
Desensitization Monitoring
Reactions on solid-phase antibody assays of pre- and post-PP serum
samples were used to evaluate antibody levels. To control for interassay
variation, the reactivity of DSA and third-party, nondonor beads were
expressed as ratios to the positive controls in each assay. The percentage of
antibodyreductionwas thendetermined fromthesenormalizedvalues. In the
absence of established risk levels for DSA, tominimize the risk of engraftment
failure, the goal was to reduce DSA levels to weak or negative reactivity,
(ie, levels that would be well below those consistent with positive ﬂow
cytometric crossmatch tests). The target levels varied for different DSA
speciﬁcities as the correlationwith positive crossmatch tests has been shown
tovarywith different antigens [17]. In general, desensitizationwasmonitored
to determine if the DSA were reduced to MFI reactivity <3000 on HLA
phenotype panels and 5000 on a single-antigen panel. For antibodies to
HLA-A, B, C, andDR antigens, based onprevious correlationswith crossmatch
tests, these levels would be well below that detectable in a ﬂow cytometric
crossmatch assay. As noted above, a higher cutoff was applied for 1 patient
withantibody toanHLA-DPantigenmeasuredon single-antigenpanel assays.
Engraftment Monitoring
Engraftment was evaluated at days þ30, þ60, and þ180 via micro-
satellite PCR detection of peripheral blood chimerism for both total
Table 1
Patient Characteristics
Variable Result
Number evaluable 296
Patient age, years
Median (range) 55 (1-74)
30 20 (6.75%)
31-40 31 (10.5%)
41-50 56 (18.9%)
51-60 90 (30.4%)
61-70 79 (26.7%)
>70 20 (6.75%)
Male 185 (62.5%)
Female 111 (37.5%)
Parous 63 (56.8%)
Null parous 48 (43.2%)
Illness
Myeloid leukemias 97
Lymphoid leukemias 41
High-grade lymphomas 80
Low-grade lymphomas 53
Multiple myeloma 6
Aplastic anemia 2
In-born errors of metabolism 15
Other 2
Table 2b
Characterization of the DSA for the 42 Candidates with DSA
DSA to Donors Evaluated (N) Weak DSA* Moderate-to-Strong DSAy
Haploidentical (117) 37 (31.6%) 80 (68.4%)
Mismatched unrelated (15) 8 (53.3%) 7 (46.7%)
DSA indicates donor-speciﬁc antibodies.
Data are presented as n (%).
* Number and percentage of donors to whom there was only weak DSA
detected (median ﬂuorescence values (MFI) values between 1000 and 3000
on solid-phase immunoassay).
y Number and percentage of the donors to whom the DSA level was
moderate-to-strong (MFI values 3000 to >15,000 on phenotype assays,
except for antibodies to HLA-DP antigens).
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as 5%, but <95%, donor. Full-donor chimerismwas deﬁned as 95% donor.
RESULTS
The study group consisted of 296 patients: 111 (37.5%)
females and 185 (62.5%) males. Patient characteristics are
provided in Table 1. A total of 957 donors were evaluated,
including 853 related (741 [86.9%] mismatched and 112
[13.1%] matched) and 104 unrelated donors. The overall
incidence of any anti-HLA antibodies, whether directed
against donor-mismatched antigens or against third-party
antigens, was 23% (Table 2a). The incidence of anti-HLA
antibodies was higher among females than males, (43.2
versus 10.8%, P < .0001), and substantially higher among
parous compared with nulliparous females (52.4% versus
31.3%, P ¼ .026).
DSA
DSA to 1 or more potential donors were found in 43
(14.5%) BMT candidates. DSA were detected against 117
potential haploidentical donors and 15 unrelated donors
mismatched for 1 or more HLA alleles. DSA were most
commonly detected in female patients (30.6% versus 4.9%, P
< .00001), with prior pregnancy increasing the risk of DSA
(42.9% versus 12.5%, P ¼ .0005, Table 2a), The DSA, based on
the relative strength in antibody assays, had moderate to
strong reactivity against 80 (68.4%) of the haploidentical
donors and 7 (46.7%) of the unrelated donors (Table 2b).Table 2a
The Overall Incidence of Any HLA-Speciﬁc Abs and DSA by Gender and
Pregnancy History
Patient Group (N) Any HLA-Speciﬁc
Abs
Donor HLA-Speciﬁc
Abs
All candidates (296) 68 (23.0%) 43 (14.5%)
Males (185) 20 (10.8%) 9 (4.9%)
Females (111) 48 (43.2%) 34 (30.6%)
Parous females (63) 33 (52.4%) 27 (42.9%)
Nulliparous females (48) 15 (31.3%) 6 (12.5%)
HLA indicates human leukocyte antibodies; Abs, antibodies; DSA, donor-
speciﬁc antibodies.
Data are presented as n (%).Of the 32 females with DSA, antibody formationwas most
frequently detected against their children. Similarly, DSA of
moderate-to-strong strength was more commonly encoun-
teredagainst their children than their siblingsorparents (data
not shown). Only 9 male candidates exhibited DSA and, not
surprisingly, were found equally against children, siblings,
and parents. Only 2 males had moderate-to-strong DSA.
Desensitization
Nine patients without other viable donor options, but
who remained otherwise excellent BMT candidates, under-
went desensitization (Table 3). Desensitization was per-
formed against 7 haploidentical related donors and against 2
mismatched, unrelated donors. One of the unrelated donors
was mismatched for 3 HLA alleles; the other was mis-
matched only for a single HLA-DPB1 allele. Six of the 9
patients were broadly sensitized with antibodies reactive
with 92% to 99% of potential donors as estimated by their
CPRA values. Three patients were more moderately sensi-
tized with CPRAs of 44%, 47%, and 51% (patients 1, 3, and 9,
respectively).
All of the patients who underwent desensitization had
starting DSA levels consistent with positive crossmatches. In
5 cases, the DSA levels detected in the solid-phase immu-
noassays were conﬁrmed ﬂow cytometric crossmatch posi-
tive in actual tests. The strongest antibody levels were
observed in patient 7, whose donor crossmatch was positive
in a complement-dependent cytotoxicity test with a 2-fold
dilution titer of 8.
Desensitization substantially reduced the DSA levels in all
9 patients after an average of 5.3 treatments with a mean
reduction in DSA of 68.1% at the end of treatment (Table 4).
Only expected toxicities occurred during the PP. After
desensitization, 8 patients’ DSA were well below levels
associated with positive ﬂow cytometric crossmatches with
an average of 1742  1560 MFI on solid-phase immunoassay
phenotype panels (data not shown). Of note, further DSA
reductions occurred after alloBMT and the last PP/IVIG,
resulting in an average DSA reduction of 94.9% at last follow-
up. Based on MFI values <500 in HLA single-antigen assays,
patients 2, 3, 5, 8, and 9 could be considered to have
completely cleared their DSA. Interestingly, the reduction of
nondonor or third party HLA antibodies was less
pronounced. Among 5 patients who had third-party anti-
bodies of comparable strength to their DSA, the average
antibody reductionwas only 37% at the end of treatment and
36% at last follow-up.
After a reduction of DSA to negative or weak levels, eight
of the 9 patients proceeded to alloBMT. Despite an initial 65%
decrease in DSA level for patient 7, no further reduction was
achieved after the fourth treatment. The DSA rebounded
Table 3
Extent of Sensitization among Nine Desensitized Patients
Patient No. Pre-PP CPRA* DSA HLA Speciﬁcity Crossmatch Testsy Additional Risk Factors Donors Evaluated
Class I Class II Related Unrelated
1 44 0 B7 CDC child to mother 2 children 4
vFCXMþ 2 siblings
2 98 94 DP1 CDC 1 sibling 1
vFCXM
3 47 0 A2 CDC child to mother 2 children 0
vFCXMþ
4 0 96 DR13, DR52, DQ6 FCXMþ multiple DSA 2 children 5
2 siblings
5 63 99 DR16 FCXMþ 1 child 5
2 parents
3 half-siblings
2 cousins
6 0 99 DQ4 FCXMþ 2 children 6
3 siblings
7 55 92 A2 CDCþ DSA strength 2 siblings 0
Titer 8 2 parents
8 98 0 A3,B27 FCXMþ child to mother 3 children 1
3 half-siblings
9 0 51 DR4,DR53 FCXMþ repeat DR4,DR53 mismatches 2 siblings 0
2 parents
Mean 45.0 59.0
SD 38.9 46.6
PP indicates plasmapheresis; CPRA, calculated panel reactive antibody; CDC, complement-dependent cytotoxicity crossmatch; FCXM, ﬂow cytometric cross-
match; vFCXM, virtual FCXM when actual crossmatch was not performed, but antibody levels were consistent with positive results.
* The CPRA valueswere based on the frequencies for HLA antigens towhich patients had antibodies at strengths consistentwith positive complement dependent
cytotoxicity and/or ﬂow cytometric crossmatches. Accessed from: http://optn.transplant.hrsa.gov/resources/professionalResources.asp?index¼78, CPRACalculator.
y Crossmatch results correlate with the following median ﬂuorescence values (MFI) from the solid-phase immunoassays: FCXMþ on phenotype panels
5000; FCXMþ on single-antigen panels 10-15,000 MFI; positive complement-dependent cytotoxicity crossmatch (CDCþ)  10,000 on a phenotype panel.
Table 4
Alloantibody Reduction after Desensitization
Patient No. Number of PP/IVIG
Treatments
% Antibody Reduction*
DSA Third-Party Antibodiesy
EOTz F/ux EOT F/u
1 7 93.9
2k 5 59.5 93.8 46.9 16.4
3 3 33.1 96
4 - DSA 1 3 86 99.1 83.4 83.8
4 - DSA 2 82 98.6
4 - DSA 3 81.6 98.7
5 5 52.1 96.9 11.4 29.5
6 4 44.3 73 4.3 6.4
7 7 64.7
8 3 74 99.9 39.1 76.8
9 11 77.4 98.4
Mean 5.3 68.1 94.9 37.0 36.0
SD 2.6 19.0 8.4 31.5 43.6
PP indicates plasmapheresis; IVIG, intravenous immunoglobulin; DSA,
donor-speciﬁc antibody; EOT, end of desensitization treatment; F/u, follow-
up.
* To control for inter-assay variation, test median ﬂuorescence values
(MFI) were expressed as a ratio to the positive control value in each assay.
The percentage of antibody reduction from the pretreatment level was
determined using these normalized values.
y Five patients had nondonor, third-party antibodies that were compa-
rable in strength to the donor-speciﬁc antibodies. The percent reduction is
given for the highest reactive antibodies.
z Desensitization treatment for patients 5, 6, and 9 included 1 plasma-
pheresis/IVIG treatment day þ1.
x The percent reduction at last follow-up calculated from normalized MFI
values. Based on MFI values < 500, patients 2, 3, 5, 8 and 9 could be
considered to have cleared their DSA completely.
k Patient 2 received additional PP and intravenous IVIG treatments
because of a delay in availability of the unrelated donor. The number listed
corresponds to the treatments immediately before transplant. No substan-
tial reduction was achieved in DSA for patient 9 until the third PP/IVIG, and
additional treatments, including 1 on day þ1, were scheduled to achieve
sufﬁcient reduction and accommodate the delay in the pretransplantation
conditioning.
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crossmatch level andwas deemed too high-risk to proceed to
transplantation. Full donor engraftment occurred for all 8
transplanted patients. Two patients developed grade 1,
cutaneous GVHD, and 1 patient developed chronic dermal
GVHD. Four patients suffered AML recurrence ranging from 3
to 16 months, despite retaining donor hematopoiesis
(Table 5). No DSA increase was observed post-
transplantation. The course of antibody reduction is illus-
trated in Figure 1 for a patient with DSA and third-party
antibodies; by day þ31, this patient’s DSA was <500 MFI,
but there was only a 6.4% reduction in third-party antibodies.DISCUSSION
The use of haploidentical donors eliminates one of the
remaining barriers to alloBMT donor availability. However,
DSA, a phenomenon not encountered with fully HLA-
matched donors, increases the risk of graft failure [10].
Additionally, DSA only detectable by highly sensitiveTable 5
Post-transplantation Clinical Status
Patient
No.
Donor
Chimerism*
GVHD Disease
Relapse
Follow-Up Time
(Months)y
1 100% no no 35
2 94% no 3 months died: 17 months
3 >95% no 5 months died: 7 months
4 100% chronic skin no 21
5 100% grade 1 skin 12 months died: 18 months
6 100% no 16 months 18
8 100% grade 1 skin no 7
9 100% no no 3
* Degree of donor chimerism determined at transplant day þ60.
y Continued donor hematopoiesis was documented for all patients at last
follow-up.
Figure 1. The antibody course during desensitization and posthematopoietic stem cell transplantation is illustrated for patient 5. The donor-speciﬁc antibody (DSA) is
shown by the line with closed circles. Third-party antibody course is illustrated by the line with squares and the positive control values for each assay are indicated by
the triangles. The relative antibody strength is indicated by the mean ﬂuorescence intensity values (MFI) determined with single-antigen immunoassays. Before
desensitization, the DSA resulted in a positive ﬂow cytometric crossmatch (FCXMþ).
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failure [12-16,24]. Although the adverse impact of DSA on
alloBMT outcomes is well recognized, their overall incidence
is unknown. Ciurea et al. [12] reported a 21% incidence of
DSA in 28 haploidentical alloBMT patients with 14% having
clinically signiﬁcant DSA to 1 or more potential mismatched
donors. In our series of 294 screened alloBMT candidates, we
report an overall DSA incidence of 14% and a 42% incidence in
parous females.
The criteria for what constitutes prohibitive DSA levels are
unknown. Importantly, solid-phase assays are variable and
subject to interference from elevated IgM antibodies, immune
complexes, and extrinsic factors, including therapeutic
monoclonal antibodies [17,18]. Moreover, there is no estab-
lished positive reference range, with reported positive cutoff
values ranging from 500 to 2000 MFI [12,15]. We based our
evaluation of DSA among alloBMT candidates on our institu-
tional experience that used these assays for screening and
monitoring solid organ allograft recipients [17,18,21-23].
Because the best correlations were obtained using single HLA
class I or class II antigen phenotype panels as targets, these
assays were used for assessing relative antibody strength. For
some antibodies, particularly for antibodies to HLA-DP anti-
gens that cannot be identiﬁed on phenotype panels, relative
strength was assessed on HLA single-antigen panels. As the
single-antigen assays are more sensitive than the phenotype
assays, patients positive on a phenotype assay were substan-
tially more reactive on the single-antigen assays.
From the experience with desensitization for renal
transplantation, the most signiﬁcant factors associated with
successful desensitization are initial DSA strength and the
antibody speciﬁcity [26,27]. Based on crossmatch test
correlations, we classiﬁed antibodies as weak (MFI values
from 1000 to 3000) or as moderate-to-strong (MFI values
ranging from 3000 to >15,000). By these criteria, weak
antibodies are predictably negative in a ﬂow cytometric
crossmatch test. Given no established level of DSA that
increases the risk of engraftment failure in alloBMT, for
monitoring the patients who underwent desensitization, the
goal was set to reduce DSA to weak or negative levels ofreactivity (ie, at levels that would be well below those
associated with a positive ﬂow cytometric crossmatch). DSA
levels consistent with either a positive cytotoxicity or ﬂow
cytometric crossmatch were considered as absolute contra-
indications to alloBMT. Because the ﬂow cytometric cross-
match is recognized to be signiﬁcantly more sensitive than
the complement-dependent cytotoxicity test [25], correlated
weak or negative DSA levels in solid-phase assays were
considered acceptable for alloBMT. The successful engraft-
ment of the 8 patients whose DSA levels were reduced to
such low levels is suggestive that this approach is valid. The
failure to adequately reduce the DSA levels in patient 7 is
likely attributable to a high starting DSA level, as this patient
had the highest DSA titer. Moreover, the patient had expe-
rienced a substantial increase in antibody titer a few weeks
before initiation of desensitization after an emergent
appendectomy. Increasing antibody titers associated with
ongoing immune responses have been noted to reduce the
likelihood of successful desensitization [19].
Although most centers consider strong DSA levels
a contraindication for alloBMT, our data suggest this should
not be an absolute barrier. After desensitization, 8 of 8
transplanted patients engrafted. Although we cannot estab-
lish that primary nonengraftment would have deﬁnitely
occurred without desensitization, available data suggest
a75%primaryengraftment failure rate in suchpatients [12]. In
fact, sincemany centers nowexclude sensitized patients from
BMT, a randomized trial is probably unethical. To our
knowledge, 2 other desensitization BMT reports have been
published: Ciurea et al. reported successful engraftment in 3
of 4 patients after PP and rituximab reduced their DSA to low/
negative levels and the 1 patient with persistent DSA expe-
rienced graft failure [12]; Yoshihara et al. reported that PP and
rituximab produced only a temporary reduction in DSA in 2
patients [28]. The higher rate of successful DSA reduction in
our series may reﬂect our desensitization regimen. It should
benoted that it is very important tomonitorDSA levels during
desensitization, as illustrated by the course of patient 9
(Table 4)whose treatment planneededmodiﬁcationwhenno
DSA reduction was noted until the third PP/IVIG.
D.E. Gladstone et al. / Biol Blood Marrow Transplant 19 (2013) 647e652652DSA reduction continued after hematopoietic stem cell
transplantation in the 8 patients successfully transplanted. A
similar, continued post-transplantation decline in DSA has
been observed in renal transplant patients. Interestingly,
among desensitized renal transplant patients, antibody
reduction was found to be signiﬁcantly higher for DSA than
for third-party antibodies, with 89% of patients losing DSA
versus 19% demonstrating reductions in third-party anti-
bodies [27]. Greater reduction of DSA was also noted among
5 of our desensitized HCT patients than for third-party
antibodies of comparable strength, with an average 94.9%
reduction of DSA at last follow-up compared with 36% of
third-party antibodies. Two possibilities may account for this
divergence: (1) the post-transplantation cyclophosphamide,
which is thought to reduce the incidence of GVHD through
elimination of alloreactive T lymphocytes and may have
a similar effect against alloreactive B lymphocytes, resulting
in the continued DSA decline [29]; or (2) engrafting donor
cells may have absorbed circulating antidonor HLA anti-
bodies resulting in the DSA decline.
Although our experience has shown that DSA can be
reduced sufﬁciently by desensitization to permit successful
alloBMT, it should be reserved for those patients with no or
limited other treatment options. Such candidates would
include those with very broad HLA sensitization, which
would rule out most, if not all, HLA-mismatched donors or
those whose disease status would not permit the time
required for an unrelated donor search. Thorough analysis of
DSA speciﬁcity and strength before initiating desensitization
is critical to determine both the extent of treatment that may
be required and the likelihood of success. If possible, alter-
native transplant or treatment options should be considered
for patients with very strong DSA levels. Despite these
caveats, our results have established that the presence of
DSA need not be an absolute barrier to HLA-mismatched
alloBMT.
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